Recovery is the goal where this category is sold most confidently and evidenced most thinly. That is not a comment on the compounds. It is a description of the published record, and it is the most useful thing a page like this can tell you. Batch certificates are published on our certificates page.
BPC-157 as an Investigational Peptide Therapeutic: translational development barriers. PMC13210877; Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. PMID 40756949; Thymosin beta-4 ophthalmic solution for dry eye: randomised placebo-controlled Phase II. PMID 26056426; ClinicalTrials.gov NCT01387347; ClinicalTrials.gov NCT00832091
BPC-157: three decades of work, no completed Phase II
The preclinical literature (summarised in our BPC-157 & TB-500 overview) is genuinely large: tendon, ligament, muscle, bone and gastrointestinal models, with reported effects on angiogenesis, collagen synthesis and fibroblast activity.
Development reviews are blunt about where that leaves it: no approved formulation, no validated dosing regimen, no completed Phase II clinical trial. Human exposure has been limited to safety trials, including a programme in inflammatory bowel disease under the code PL14736.
There is a structural problem with the literature that commercial pages rarely mention. Analyses by author affiliation attribute more than eighty per cent of published BPC-157 studies to a single research group at the University of Zagreb. Independent replication across separate laboratories is the normal precondition for treating preclinical findings as robust.
That cuts both ways, which is why we state it rather than bury it: it weakens the efficacy case and it weakens any claim that adverse effects have been ruled out.
TB-500: real human trials, wrong route
Thymosin beta-4 has been through registered human trials: a Phase II in dry eye (NCT01387347), a placebo-controlled dose-response study in venous stasis ulcers (NCT00832091), and a Phase III programme in neurotrophic keratopathy.
Read the route carefully. Those studied topical and ophthalmic administration for eye-surface and wound-healing indications. They are not trials of systemic injection for tendon, ligament or muscle repair, which is what almost everyone looking at this category has in mind.
The human safety and efficacy record exists. It exists for a different route, a different formulation and a different indication.
There is also a molecule question: TB-500 as sold is commonly a fragment rather than full-length thymosin beta-4, so trial data on the full-length protein does not automatically describe it. The certificate of analysis is where that gets settled, not the marketing copy.
The combination has never been tested
BPC-157 and TB-500 are supplied together, as one combined pen, on the rationale that they act on different parts of tissue repair (the pairing is set out on the repair peptides class page). No published human trial has administered both and measured the outcome. The rationale is mechanistic; the combination itself has no direct evidence behind it.
What about the GH-axis compounds listed here
CJC-1295/Ipamorelin appears under recovery on the reasoning that growth hormone is involved in tissue repair, and under sleep on the same reasoning. The published human work on that pairing measured GH and IGF-1 concentrations, not repair. Same caution as on the muscle page: a biomarker moved, an outcome was not measured.
MOTS-c (what MOTS-c is) appears here on metabolic grounds, as it does under peptides for energy, and is entirely preclinical.
Why we publish this rather than a recovery timeline
Every incentive in this market points toward a confident “faster return to training” claim. There is no controlled human evidence supporting one for these compounds by this route, and inventing a timeline would be the easiest thing on this page to do and the least defensible.
What we can evidence is what is in the pen: identity, content, purity, sterility and batch traceability, tested by an independent laboratory with the certificate reachable from the QR code. Fuller treatment at BPC-157 and TB-500 dosing in the literature and reported adverse events.
